自体CIK细胞联合CLAG-M方案在挽救治疗复发难治性急性髓系白血病患者中的应用分析  

Application Analysis of Autologous CIK Cells Combined with CLAG-M Regimen in the Rescue and Treatment of Patients with Relapsed and Refractory Acute Myeloid Leukemia

作　　者：谢凤玲[1] XIE Fengling(Department of Hematology,Shanxian Central Hospital,Shanxian,Shandong Province,274300 China)

机构地区：[1]单县中心医院血液内科,山东单县274300

出　　处：《世界复合医学》2021年第5期7-11,共5页World Journal of Complex Medicine

摘　　要：目的观察自体细胞因子诱导杀伤细胞(CIK)联合CLAG-M方案在挽救治疗复发难治性急性髓系白血病(RR-AML)患者的应用效果。方法以该院2016年8月—2019年8月收治的56例RR-AML患者为研究对象,依据数字表法随机分为两组,各28例,分别为CLAG-M方案治疗(对照组)、自体CIK细胞联合CLAG-M方案治疗(观察组),对比分析不同治疗方法的应用效果。结果观察组总有效率为92.86%,早期肿瘤缓解率为71.43%均高于对照组的71.43%、42.86%,差异有统计学意义(χ^(2)=4.383、4.667,P<0.05);观察组不良反应总发生率为10.71%,低于对照组的35.71%,差异有统计学意义(χ^(2)=4.909,P<0.05);观察组无进展生存期(PFS)为(21.06±1.66)个月、总生存期(OS)为(20.35±1.52)个月均长于对照组的(18.23±1.23)、(16.52±1.23)个月,差异有统计学意义(t=7.248、10.365,P<0.05)。结论经自体CIK细胞联合CLAG-M方案治疗,可有效改善RR-AML患者的临床病症,促使肿瘤尽早缓解,延长患者生存期,且不良反应较少,值得推广。Objective To observe the effect of autologous cytokine-induced killer cells(CIK)combined with CLAG-M regimen in the rescue and treatment of patients with relapsed and refractory acute myeloid leukemia(RR-AML).Methods 56 RR-AML patients admitted to the hospital from August 2016 to August 2019 were taken as the research objects.According to the digital table method,they were randomly divided into two groups,28 cases in each group,respectively treated with CLAG-M regimen(control group),autologous CIK cells combined with CLAG-M regimen treatment(observation group),comparative analysed of the application effects of different treatment methods.Results The total effective rate of the observation group was 92.86%,and the early tumor remission rates of 71.43%were higher than those of the control group 71.43%and 42.86%.The difference was statistically significant(χ^(2)=4.383,4.667,P<0.05);adverse reactions rate was 10.71%in the observation group lower than that of 35.71%of the control group.The difference was statistically significant(χ^(2)=4.909,P<0.05);the progression-free survival(PFS)of the observation group was(21.06±1.66)months,and the overall survival(OS)was(20.35±1.52)months were longer than(18.23±1.23)months and(16.52±1.23)months in the control group.The difference was statistically significant(t=7.248,10.365,P<0.05).Conclusion The treatment of autologous CIK cells combined with CLAG-M regimen can effectively improve the clinical symptoms of RR-AML patients,promote early remission of tumors,prolong patient survival,and have fewer adverse reactions.It is worthy of promotion.

关 键 词：自体CIK细胞 CLAG-M方案 RR-AML 治疗效果 

分 类 号：R733.71[医药卫生—肿瘤]